Form 4: PTC Therapeutics CFO Sells Shares for Tax Obligations

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,992 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Pierre Gravier, Chief Financial Officer of PTC Therapeutics, Inc. (PTCT), reported a sale of common stock.
• The transaction involved the disposition of 2,992 shares of common stock.
• The shares were sold at a price of $69.36 per share.
• The sale was executed on February 18, 2026.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs (from a 19,000 RSU grant on February 15, 2024) and 1,550 RSUs (from a 3,100 RSU grant on February 15, 2024).
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Pierre Gravier beneficially owns 87,318 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a non-discretionary 'sell to cover' transaction for tax purposes, which is a routine occurrence for executive equity compensation and does not reflect a change in management's outlook or a discretionary divestment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary sale.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common practice for executives receiving equity compensation, allowing them to meet tax obligations upon RSU vesting without a discretionary market sale. This is a routine disclosure for publicly traded companies.

Related Party Transactions

• The transaction involves the Chief Financial Officer, Pierre Gravier, selling company stock, which is a related party transaction. However, it is a routine 'sell to cover' for tax purposes related to RSU vesting.

Stakeholder Impact

• Minimal direct impact on shareholders as it is a routine, non-discretionary sale for tax purposes by an executive.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by the CFO to satisfy tax obligations upon RSU vesting. Such non-discretionary sales are common and generally do not indicate a change in the company's fundamentals or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Trading, Stock Sale, CFO, Pierre Gravier, RSU Vesting, Tax Withholding, 10b5-1 Plan